Intellia faces backlash after halting drug work and layoffs, despite strategic decisions to focus on best ideas. Click here to find out why NTLA is a Sell.

In a report released today, Alec Stranahan from Bank of America Securities maintained a Buy rating on Intellia Therapeutics (NTLA – Research ...

The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...

NEW YORK, NY / ACCESSWIRE / January 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia ...

Copyright © 2024 MarketWatch, Inc. All rights reserved.

His influence is partly the result of a very online political establishment, and partly thanks to a right-leaning media that is hostile to Keir Starmer’s Labour government. By Mark Landler The ...

Covering Netflix News Independently Since 2013. What’s on Netflix is not owned by or affiliated with Netflix or any of its partners in any capacity. The authors of this site also have no affiliation ...